
    
      After a screening period of up to 2 weeks followed by a pretreatment period of 2 or 10 weeks,
      each participant will be receiving assigned double-blind treatment (omarigliptin 25 mg or
      placebo once weekly) for approximately 16 weeks (Phase A) followed by 36 weeks of open-label
      treatment (omarigliptin 25 mg once weekly, Phase B). After the end of treatment each
      participant will be followed for 21 days.
    
  